Richter: JPM upbeat about bipolar depression drug

Gedeon Richter

16/04/2019 08:18

** JP Morgan raises Hungarian drugmaker  GDRB.BU  to
"overweight", citing "stellar" sales growth for bipolar
depression drug, Vraylar
    ** Broker says YTD Vraylar volumes for existing indications
have been growing twice faster than consensus estimates 
    ** JPM expects "a positive May catalyst with a 66%
probability of Vraylar's label extension to treat bipolar
depression patients"
    -- Vraylar's current indication is to treat both the manic
and mixed episodes of bipolar I disorder and is currently
awaiting FDA decision expected in May to approve Vraylar to
treat depressive episodes

    

    
   




 ((anna.jaworska-guidotti@tr.com))